Tag Archives: dana farber cancer institute
Study examines drug regimen for the treatment of non-small cell lung cancer among older patients
Public release date: 17-Apr-2012[ | E-mail | Share ] Contact: Anne Doerr anne_doerr@dfci.harvard.edu617-632-5665JAMA and Archives Journals WASHINGTON, D.C. Analysis of a drug regimen approved by the F.D.A. in 2006 for the treatment of non-small cell lung cancer (bevacizumab added to the standard chemotherapy regimen carboplatin and paclitaxel) finds Medicare insured patients age 65 years and …
